n

(%)

Median Survival

All patients

935

100

16.0 months

Deceased patients

Therapy associated

22

4.7

2.4 months

Intercurrent disease

160

34.0

13.2 months

Locoregional progression ± metastasis

117

24.9

13.6 months

Metastasis and locoregional control

86

18.3

14.6 months

Second malignant disease

85

18.1

34.5 months